GSK ’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus

GSK ’s human monoclonal antibody Benlysta (belimumab) has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to treat adult patients with systemic lupus erythematosus (SLE), a chronic, incurable, autoimmune disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news